NEW OPPORTUNITIES OF THERAPY OF SEVERE ATOPIC DERMATITIS

The article presents a case of successful use of the drug Dupilumab in a 21-year-old patient with severe atopic dermatitis, concomitant bronchial asthma and allergic rhinitis. The patient was observed in the allergological department of the Krasnoyarsk Clinical Regional Hospital for 2 years. The disease was characterized by constant skin symptoms, frequent exacerbations, resistance to standard therapy, including systemic glucocorticosteroids and cytostatics. Considering the above factors, it was decided to begin targeted therapy with Dupilumab, registered in the Russian Federation for use in atopic dermatitis resistant to standard therapy. Against the background of biological therapy (13 injections were carried out), a stable significant decrease in skin syndrome activity was achieved (SCORAD index decreased from 72 to 9 points), the patient's quality of life significantly improved.